ADMA Biologics, Inc. (ADMA)
9.72
-0.21
(-2.11%)
USD |
NASDAQ |
Oct 02, 16:00
9.72
0.00 (0.00%)
After-Hours: 20:00
ADMA Biologics Enterprise Value : 2.258B for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 2.258B |
| October 01, 2026 | 2.306B |
| September 30, 2026 | 2.328B |
| September 29, 2026 | 2.312B |
| September 28, 2026 | 2.348B |
| September 25, 2026 | 2.182B |
| September 24, 2026 | 2.213B |
| September 23, 2026 | 2.254B |
| September 22, 2026 | 2.279B |
| September 21, 2026 | 2.210B |
| September 18, 2026 | 2.121B |
| September 17, 2026 | 2.085B |
| September 16, 2026 | 2.073B |
| September 15, 2026 | 2.008B |
| September 14, 2026 | 2.128B |
| September 11, 2026 | 2.148B |
| September 10, 2026 | 2.184B |
| September 09, 2026 | 2.197B |
| September 08, 2026 | 2.218B |
| September 04, 2026 | 2.236B |
| September 03, 2026 | 2.227B |
| September 02, 2026 | 2.211B |
| September 01, 2026 | 2.170B |
| August 31, 2026 | 2.184B |
| August 28, 2026 | 2.173B |
| Date | Value |
|---|---|
| August 27, 2026 | 2.204B |
| August 26, 2026 | 2.238B |
| August 25, 2026 | 2.258B |
| August 24, 2026 | 2.220B |
| August 21, 2026 | 2.285B |
| August 20, 2026 | 2.267B |
| August 19, 2026 | 2.333B |
| August 18, 2026 | 2.218B |
| August 17, 2026 | 2.173B |
| August 14, 2026 | 2.202B |
| August 13, 2026 | 2.188B |
| August 12, 2026 | 2.272B |
| August 11, 2026 | 2.300B |
| August 10, 2026 | 2.265B |
| August 07, 2026 | 2.299B |
| August 06, 2026 | 2.335B |
| August 05, 2026 | 2.155B |
| August 04, 2026 | 2.076B |
| August 03, 2026 | 2.037B |
| July 31, 2026 | 1.974B |
| July 30, 2026 | 2.022B |
| July 29, 2026 | 2.031B |
| July 28, 2026 | 2.049B |
| July 27, 2026 | 1.979B |
| July 24, 2026 | 1.932B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Vericel Corp. | 1.987B |
| BioMarin Pharmaceutical, Inc. | 14.41B |
| Emergent BioSolutions, Inc. | 772.03M |
| Exelixis, Inc. | 13.86B |
| Akebia Therapeutics, Inc. | 288.61M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 37.82M |
| Revenue (Quarterly) | 124.40M |
| Total Expenses (Quarterly) | 86.57M |
| EPS Diluted (Quarterly) | 0.1642 |
| Gross Profit Margin (Quarterly) | 69.31% |
| Profit Margin (Quarterly) | 30.40% |
| Earnings Yield | 7.25% |
| Operating Earnings Yield | 9.29% |
| Normalized Earnings Yield | 7.312 |